Dr. Dan Zhang is the co-founder and co-chairman of Jiangsu Hillgene Biopharma Co., Ltd., a CDMO specializing in cell therapy drugs, dedicated to providing innovative solutions. He is the Global Biotechnology Advisory Committee Chairperson at Frost & Sullivan and a specially invited expert for the China Federation of Returned Overseas Chinese.

Previously, Dr. Zhang was the Executive Chairman of Fountain Medical Development Ltd. (now ClinChoice), a global clinical CRO with over 4,000 employees across Asia, Europe, and the USA. Before that, he served as Head of Clinical Development and Safety Assessment at Sigma-Tau Research Inc., an Italian pharmaceutical company. He was also Vice President at Quintiles Transnational Corp., the world’s largest clinical CRO, and Chairman of Quintiles Medical Development (Shanghai) Co., Ltd.

Dr. Zhang is a member of the National Drug Development Fund Grant Review Committee and a consultant for the National Medical Products Administration (NMPA). He is a member of the ICH E19 Expert Working Group, chairs the Pharmaceutical R&D Committee of the China Pharmaceutical Industry Research and Development Association, and serves as a senior consultant to the Chinese Academy of Medical Sciences. He has held leadership roles in SAPA, CBA-USA, and BayHelix, where he chairs the Government Relations Committee.

Dr. Zhang earned his M.D. from Peking Union Medical College, followed by an MPH in Health Policy and Management from Harvard and a Master’s in Healthcare Management from Wharton Business School at the University of Pennsylvania.